researcher comment: hif-2α inhibition in rcc | toni chouieri
Published 4 years ago • 203 plays • Length 2:37Download video MP4
Download video MP3
Similar videos
-
3:12
researcher comment: the fraction-rcc study | toni choueiri
-
1:19
hif-2 inhibitors in rcc
-
1:51
kidney cancer research: hif-2α inhibition
-
3:16
toni choueiri, md, provides updates on hif-2 alpha inhibitors in renal call cancer
-
1:40
dr. choueiri on checkpoint inhibitor/tki combinations in rcc
-
5:44
hcrn-gu16-260: nivolumab and salvage nivolumab-ipilimumab in patients with advanced rcc
-
22:30
vhl breakthrough: an expert discussion
-
5:08:54
circulating tumor cells 2.0 - oncodiscover
-
4:24
researcher comment: the savoir trial | toni choueiri
-
3:03
adjuvant pembrolizumab improves rcc disease-free survival | toni choueiri
-
2:01
toni choueiri, md, considers the next steps in the further development of hif-2 inhibitors
-
2:06
dr. choueiri on phase i/ii data of mk-6482 in advanced clear cell rcc
-
2:21
phase ii study of the oral hif-2α inhibitor mk-6482 for vhl ccrcc: update
-
1:41
dr. choueiri on next steps for treatment in rcc
-
3:29
targeting hif-2a in the management of vhl-associated rcc
-
4:53
researcher comment: sitravatinib plus nivolumab in advanced rcc | pavlos msaouel
-
0:52
dr. choueiri on the role of cabozantinib in rcc
-
1:37
dr. choueiri on synergy between immunotherapy and vegf inhibitors in rcc
-
2:48
oral hif-2 α inhibitor mk-6482 in patients with advanced clear cell renal cell carcinoma
-
2:21
phase ii study of the oral hif-2α inhibitor mk-6482
-
0:45
dr. choueiri on fda approval of lenvatinib/everolimus in rcc
-
0:41
dr. toni choueiri on cabozantinib and nivolumab combination in kidney cancer